

# GO-PRACTICE - Study of the conditions of use of golimumab and its impact, in current practice, in patients with chronic inflammatory rheumatism.

Head :LEVY-BACHELOT Laurie, MSD France  
Gouyette Najat, MSD France

Last update : 10/19/2017 | Version : 1 | ID : 73342

General	
Identification	
Detailed name	Study of the conditions of use of golimumab and its impact, in current practice, in patients with chronic inflammatory rheumatism.
Sign or acronym	GO-PRACTICE
General Aspects	
Medical area	Rheumatology
Pathology (details)	Rheumatoid arthritis, ankylosing spondylitis and rheumatic psoriasis
Scientific investigator(s) (Contact)	
Name of the director	LEVY-BACHELOT
Surname	Laurie
Address	34 avenue Léonard de Vinci, Courbevoie
Phone	01 80 46 41 98
Email	laurie.levy-bachelot@merck.com
Unit	MSD France
Name of the director	Gouyette
Surname	Najat
Unit	MSD France
Collaborations	
Funding	
Funding status	Private

**Governance of the database**

Sponsor(s) or organisation(s) responsible MSD France

Organisation status Private

Presence of scientific or steering committees Yes

**Additional contact****Main features****Type of database**

Type of database Study databases

Study databases (details) Cohort study

**Database objective**

Main objective To evaluate the maintenance of golimumab therapy 24 months after initial prescription in adult patients with chronic inflammatory rheumatism in clinical practice in France  
The primary endpoint is the total percentage of patients who maintained treatment with golimumab two years after the initial prescription.

**Inclusion criteria****Inclusion:**

1. Patients aged 18 years or older.
2. Patients who gave oral consent to participate after receiving oral and written information about the study.
3. Patients with a diagnosis of chronic inflammatory rheumatism.
4. Patients with an initial hospital prescription of golimumab but not yet having initiated treatment with golimumab.
5. Patients able to understand and complete the self-evaluation questionnaires

**Non-inclusion:**

1. Patients previously treated with golimumab and discontinuing treatment prior to inclusion.
2. Patients who participated in previous golimumab trials
3. Patients who had already begun treatment with golimumab prior to inclusion and were receiving

treatment at the time of inclusion.

4. Patients with pathologies or conditions that, according to the investigator, would limit the patient's ability to participate fully in the study or to meet all the requirements of the study;

## Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
-----	---

Population covered	Sick population
--------------------	-----------------

Pathology	M05-M14 - Inflammatory polyarthropathies
-----------	--

Gender	Male Woman
--------	---------------

Geography area	National
----------------	----------

Detail of the geography area	No details available
------------------------------	----------------------

## Data collection

### Dates

### Size of the database

Size of the database (number of individuals)	[500-1000[ individuals
--	------------------------

Details of the number of individuals	750 included
--------------------------------------	--------------

## Data

Database activity	Current data collection
-------------------	-------------------------

Type of data collected	Clinical data Declarative data Paraclinical data Biological data
------------------------	---

Clinical data (detail)	Direct physical measures Medical registration
------------------------	--

Declarative data (detail)	Paper self-questionnaire
---------------------------	--------------------------

Presence of a biobank	No
-----------------------	----

## Procedures

Participant monitoring	Yes
------------------------	-----

Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.) Monitoring by contact with the referring doctor
-----------------------	--

Links to administrative sources	No
---------------------------------	----

## Promotion and access

### Promotion

### Access

Terms of data access (charter for data provision, format of data, availability delay)	No data access charter
---	------------------------

Access to aggregated data	Access not yet planned
---------------------------	------------------------

Access to individual data	No access
---------------------------	-----------